Maria Palasis - 12 Feb 2022 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
President & CEO, Director
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Maria Palasis, Ph.D.
Issuer symbol
LYRA
Transactions as of
12 Feb 2022
Net transactions value
$0
Form type
4
Filing time
15 Feb 2022, 20:31:03 UTC
Next filing
18 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +127,400 $0.000000 127,400 12 Feb 2022 Common Stock 127,400 $4.78 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 12, 2022.

Remarks:

Exhibit 24 - Power of Attorney